Related Experiment Videos
Abstract:
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The economic costs of heroin addiction in the United States.
Drug and alcohol dependence·2001
The co-occurrence of smoking and binge drinking in adolescence.
Addictive behaviors·2000
The relationship between adolescent smoking and drinking and likelihood estimates of illicit drug use.
Journal of addictive diseases·2000
A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
Journal of substance abuse treatment·2022
Factors associated with the adoption of evidence-based innovations by substance use disorder treatment organizations: A study of HIV testing.
Journal of substance abuse treatment·2022
An intervention pilot to facilitate harm reduction service decentralization in Vietnam.
Journal of substance abuse treatment·2022
Housing and supportive services for substance use and self-efficacy among young mothers experiencing homelessness: A randomized controlled trial.
Journal of substance abuse treatment·2022
Digital interventions for opioid use disorder treatment: A systematic review of randomized controlled trials.
Journal of substance abuse treatment·2022
A Rat Excisional Wound Model for Investigating Therapeutics in Critical-Size Skin Wounds.
Journal of visualized experiments : JoVE·2026
Current evidence across the treatment spectrum of adrenocortical carcinoma: a comprehensive scoping review.
Endocrine oncology (Bristol, England)·2026
Combination of Palladium Nanoparticles and Tubastatin-A Potentiates Apoptosis in Human Breast Cancer Cells: A Novel Therapeutic Approach for Cancer [Retraction].
International journal of nanomedicine·2026